key: cord-0954500-7gw8taa8 authors: Srivastava, Ritika; Kumar, Anoop title: Use of aspirin in reduction of mortality of COVID‐19 patients: A meta‐analysis date: 2021-06-28 journal: Int J Clin Pract DOI: 10.1111/ijcp.14515 sha: 4a94cf8bcb4969a2fa59e30eee6ff9103b930166 doc_id: 954500 cord_uid: 7gw8taa8 COVID‐19 infection, affecting every one of us from the last year. Emerging reports have indicated thromboembolism in serious cases of COVID‐19. The aspirin is useful to reduce mortality of serious patients with acute respiratory distress syndrome without COVID‐19. Thus, we have conducted a metanalysis to find out the role of aspirin in the mortality of COVID‐19 patients using RevMan 5. A total of 10 studies containing 56 696 COVID‐19 patients were found appropriate for quantitative analysis. The quality of articles was assessed using Newcastle–Ottawa scale. The fixed‐effect model was used to calculate the odds ratio with 95% confidence interval (CI). The odd ratio was found to be 0.70 [0.63, 0.77] which indicates a lesser likelihood of having death in COVID‐19 patients in aspirin group as compared with non‐aspirin group. However, no effect 0.00 [−0.04, 0.04] was observed after the exclusion of outliers. Thus, further clinical evidence is required to make valid conclusion. following: "(COVID19 OR COVID-19 virus infection OR COVID-19 infection OR 2019 novel corona virus infection OR 2019-nCoV infection OR 2019-nCoV disease AND aspirin or acetylsalicylic acid or antiplatelet)". The PRISMA guideline was followed to conduct this study. 13 The studies were included as per the inclusion and exclusion criteria. The inclusion criteria include observational studies, COVID-19 patients, age above 18 years, and use of aspirin alone or in combinations, and the primary outcome was death. The reviews, systematic reviews, meta-analysis, case reports, animal studies, and the outcome where no death was reported were excluded. RS and AK separately have done a quality assessment of all included studies using the Newcastle-Ottawa scale (NOS). 14 The NOS is subdivided into three major headings: selection, comparability, and outcome. Each subheading has items that are as follows: four for selection, three items for the outcome, and two items for comparability subheadings. Based on NOS, studies can be categorized as: Good, Fair, and Poor quality according to the item points. The data were extracted from 10 studies. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The extracted data were included in an excel sheet that contains the columns like authors' first names, year of study, type of study, sex, the total number of subjects (non-aspirin), the number of subjects survived (nonaspirin), the total number of subjects (aspirin), and the number of subjects survived (aspirin) as mentioned in Table 1 . RevMan 5 was used for the analysis of the data. Mantel-Haenszel odds ratio (OR) with its 95% confidence intervals was calculated. The fixed-effects model was used due to less variation among studies with respect to study design, study population, and so forth. The P value < .1 was considered as significant heterogeneity among studies. The heterogenicity among studies was also estimated using the χ 2 test and the I 2 statistic. The I 2 values of 25% considered low, 50% as moderate, and 75% as high heterogenicity. The funnel plot was created for the qualitative assessment of publication bias. The initial search strategy identified 7803 studies, from inception until March 2021. One duplicate was removed. The 7717 articles were excluded based on titles. Further, 33 articles were excluded based on abstracts. Finally, the full text of 52 articles was downloaded, and 42 articles were excluded based on irrelevant information as shown in Figure 1 . Finally, 10 articles were included in a quantitative synthesis that involved 56 696 COVID-19 patients from 10 observational studies. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The one article among these 10 articles was preprint. 24 Out of 10 studies, three were conducted in the United States, two each in China and Italy, and one each in Israel, Iran, and France. All studies are retrospective except Kevorkian et al 20 that is a prospective observational study. The study characteristics were summarized in Table 1 . The quality assessment results have shown seven studies were of good quality, and the remaining three were fair, as shown in Table 2 . • Thromboembolism is one of the major reason for deaths of serious COVID-19 patients. • Aspirin is one of the well-known antiplatelet drugs. • It mainly inhibits the COX that ultimately results in the inhibition of thromboxane A2 that is responsible for thrombo-inflammation and thrombosis in patients. • Its already known that aspirin is useful to reduce mortality of serious patients with acute respiratory distress syndrome without COVID-19. • The present study was conducted to find out the role of aspirin in the reduction of mortality of COVID-19 patients • The results of the current study indicates a lesser likelihood of having death in COVID-19 patients in aspirin group as compared with non-aspirin group. Ten studies were included, with a total of 56 696 COVID-19 cases. A total of 13 705 patients were on aspirin, whereas 42 991 patients were in the non-aspirin group. The fixed-effect model was used to check the association of aspirin with mortality in COVID-19 patients. The pooled OR was found to be 0.71 [0.64, 0.78] as shown in Figure 2 , which indicates a lesser likelihood of having death in COVID-19 patients in the aspirin group as compared with the non-aspirin group. Figure 5 . We have also done the analysis after the removal of Osborne et al, 16 Viecca et al, 18 and Lodigiani et al 22 and found no effect of aspirin in the reduction of mortality of COVID-19 patients as compared with the non-aspirin group ( Figure 6 ). The I 2 statistics have shown no heterogeneity among studies after the removal of outliers. The funnel plot was used for the qualitative assessment of publication bias. The shape of the plot was found to be symmetrical ( Figure 7) , which indicates minimum publication bias. * indicates one criteria was followed, ** two criteria were followed and ***three criteria were followed. TA B L E 2 Quality assessment using the Newcastle-Ottawa scale We have only searched PubMed, Google Scholar, Clinial trials databases for relevant articles. Further, the subgroup analysis was not done due to a limited number of studies. Aspirin is useful in the reduction of mortality of COVID-19 patients. However, further evidence is required to make a valid conclusion. The authors are thankful to Vice-Chancellor, Professor (Dr) R.K. (DPSRU), New Delhi 110017, India, for his continuous support, motivation, and providing necessary facilities to carry out this work. The authors declare that they have no conflicts of interest. Ritika Srivastava extracted the data and prepared the first draft of the manuscript. Anoop Kumar cross-check the data, analysed, and prepared the final draft of the manuscript. The data that support the findings of this study are openly available in tables of the manuscript. Anoop Kumar https://orcid.org/0000-0002-7806-9986 F I G U R E 6 Pooled analysis results using a fixed-effect model (forest plot) after exclusion of Osborne et al, 16 Viecca et al, 18 and Lodigiani et al 22 Funnel plot for the assessment of publication bias Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention Acute arterial and deep venous thromboembolism in COVID-19 patients: risk factors and personalized therapy Venous thromboembolism in COVID-19 patients Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19 Hematological findings and complications of COVID-19 Prominent changes in blood coagulation of patients with SARS-CoV-2 infection COVID-19 and venous thromboembolism: a meta-analysis of literature studies Anticoagulation in COVID-19: a systematic review, meta-analysis and rapid guidance from the Mayo clinic Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Antiplatelet therapy for critically ill patients: a pairwise and Bayesian network meta-analysis. Shock Effect of antiplatelet therapy on acute respiratory distress syndrome and mortality in critically ill patients: a meta-analysis Meta-analysis of the effect of aspirin on mortality in COVID-19 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019 Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19 Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients-the COCAA-COLA cohort study The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran SARS-CoV-2 receptors are expressed on human platelets and the effect of aspirin on clinical outcomes in COVID-19 patients. Res Sq Coronavirus disease 2019: hematological anomalies and antithrombotic therapy COVID-19-associated systemic thromboembolism: a case report and review of the literature Clinical Guidance for Management of COVID-19 Patients WHO Recommends Follow-up Care, Low-Dose Anticoagulants for COVID-19 Patients How to cite this article: Srivastava R, Kumar A. Use of aspirin in reduction of mortality of COVID-19 patients: A metanalysis